Inodilators and cardio-renal syndrome

Professor Piergiuseppe Agostoni highlights that cardiorenal syndrome is part of a whole-body heart failure syndrome. Studies have shown the systemic benefits of levosimendan on physiological parameters for the heart, lung and kidney, and also on muscle oxygenation and utilisation. Levosimendan is unique in providing kidney protection by dilating the renal venous system and so reducing volume overload and renal oedema.
Professor Carsten Tschöpe comments at the end of the presentation on the importance of taking a holistic view and considering the effects of treatments not only on the heart but also on other organs in cardiogenic shock. He summarises the additional benefits of levosimendan which include the venous dilatation which reduces kidney oedema and makes it a suitable treatment for patients  with cardiogenic shock who need kidney-protective treatment.

Piergiuseppe Agostoni is Director of the Cardiovascular Fellowship Program of the University of Milan, Italy. He is chief of the cardiorespiratory pathophysiology laboratory, head of the Heart failure Unit, and coordinator of the Critical Care Cardiology Unit, Centro Cardiologico Monzino, Milan. He has authored over 800 publications, including more than 300 in international journals with an impact factor. He is president of CPX-International. He has received many awards for his work in the field of heart failure and cardiovascular research.

 

ESC 2019 resources


Login/ Register Maximise Minimise